Search clinical trials for: CC-99282

Total 828 results

The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Bristol-Myers Squibb

Recruiting

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Relapsed or Refractory T-cell Lymphomas

Japan
Celgene

Active, not recruiting

A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lymphoma, Non-Hodgkin

Canada, Spain, United States, Austria
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Follicular Lymphoma | Tumor

United States
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, Israel, Italy, Spain, United Kingdom
Celgene

Completed

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Celgene

Recruiting

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Lymphoma, Non-Hodgkin

United States, Korea, Republic of, China, Canada, France, Spain, Denmark, Brazil, Argentina, Austria, Chile, Israel, Italy, United Kingdom, Belgium
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
Radboud University Medical Center
Norgine

Unknown

Comparison of AMR and ADR Between Endocuff Vision-assisted and Conventional Colonoscopy: a Multicenter Randomized Trial (EXCEED)

Colorectal Neoplasms

Netherlands, Greece
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

Withdrawn

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain
Celgene

Recruiting

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, France, Canada
Celgene

Active, not recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Spain, Canada, United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

France, Spain
Celgene

Completed

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Japanese Pharmacokinetic Bridging Study for CC-93538

Healthy Volunteers

United States
Celgene

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

Healthy Volunteer

United States
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Clinical Pharmacology, Healthy Male Volunteer Study

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study in rFSH Patients

Infertility

Belgium
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study (CC-Test)

Pregnancy

Belgium
Celgene

Completed

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Pulmonary Fibrosis

United States, Australia
National Cancer Institute (NCI)

Completed

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

Brain and Central Nervous System Tumors

United States
Boston Medical Center

Completed

Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Celgene Corporation

Completed

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Glioblastoma | Malignant Gliomas

United States
Celgene

Withdrawn

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Sarcoidosis
Celgene

Active, not recruiting

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Glioblastoma | Astrocytoma

United States, Spain
Celgene

Active, not recruiting

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

France, Canada, United States, Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants

Healthy Volunteers

United States
Jean Edward

Completed

Coverage and Cost-of-Care (CC) Links- Financial Navigation Program (CC Links)

Financial Stress | Survivorship | Hematologic Cancer

United States
Benjamin Rose Institute on Aging

Withdrawn

SHARE for Persons With Chronic Conditions and Their Family Caregivers (SHARE-CC)

Family Caregivers | Chronic Health Conditions

United States
Celgene

Completed

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Celgene

Completed

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Sun Yat-sen University
Ministry of Health, China; Xidian University

Completed

Validation of the Utility of Rare Disease Intelligence Platform

Cataract | Artificial Intelligence

China
Kaiser Clinic and Hospital

Completed

Optimization and Follow-up of the Consecutive Use of Two Intragastric Balloons in the Treatment of Obesity

Obesity | Metabolic Syndrome

Brazil
Celgene

Active, not recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Neoplasms | Lymphoma, Non-Hodgkin

France, Italy, Japan, Spain
Celgene

Active, not recruiting

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

France, United States, Canada, Norway, Spain, United Kingdom
Celgene

Completed

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

Japan
Nobel Biocare

Completed

A 5-year Clinical Evaluation Study on NobelReplace Conical Connection Implants

Healthy | Implant
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Celgene

Completed

Radiolabeled Study of CC-122 in Healthy Subjects

Healthy Volunteers

United States
Universitair Ziekenhuis Brussel

Unknown

Multicenter Prospective Cumulus Cell Test Study (MC_CC-Test)

Pregnancy

Belgium
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Renal Insufficiency

United States
Celgene

Completed

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene Corporation

Completed

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Healthy Subjects

United States
Celgene Corporation

Terminated

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Myeloid Leukemia

United States

3

Subscribe